Document is current
Any future updates will be listed below
-
Authors
Kim, Hyeon-Young
Kim, Tae-Rim
Kim, Sung-Hwan
Kim, In-Hyeon
Kim, Woong-Il
Park, Jun-Hong
Ko, Youngho
Yun, Sungil
Park, Han-Oh
Kim, Jong-Choon https://orcid.org/0000-0002-8265-9911
-
Funding
Funding for this research was provided by:
Civil and Military Dual-use Technology Program (14-CM-EB-09)
Korea Drug Development Fund (KDDF-201706-03)
- License Information
-
More Information
Article History
Received: 6 August 2024
Revised: 5 March 2025
Accepted: 5 March 2025
First Online: 3 April 2025
Declarations
:
: The authors declare that Tae-Rim Kim, Jun-Hong Park, Youngho Ko, Sungil Yun, and Han-Oh Park are employed by siRNAgen Therapeutics and Bioneer Corporation, which developed SAMiRNA-AREG, and had no influence on the evaluation of the test substance used in this study.
: The Institutional Animal Care and Use Committee of Korea Institute of Toxicology (Jeongeup, Republic of Korea) reviewed and approved all experimental procedures (approval number: 1808-0305, 1901-0003).
: Informed consent was obtained from all individual participants included in the study.
